Vitro Diagnostics Announces New Stem Cell Product to Support Clinical Trials Expanding Vitro’s Pipeline that Includes Patent-Protected Adult Stem Cells

GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, known for "Harnessing the Power of Cells," is announcing the addition of a new serum-free stem cell growth medium to its existing product lineup that includes patented adult stem cell lines. Vitro's newest advance is added to a roster that includes a recently patented cell line derived from human pancreatic tissue, patents for production of FSH, methods and compositions for production of immortalized human cells, and adult stem cells. Vitro also owns patent-pending technology for stem cell therapy of cancer.
MORE ON THIS TOPIC